Vitreous Floaters Clinical Trial
Official title:
Low Dose Atropine For Symptomatic Vitreous Floaters
| Verified date | December 2023 |
| Source | Prism Vision Group |
| Contact | Jeanette Du, MD |
| Phone | 844-749-3627 |
| JDu[@]rgw.com | |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.
| Status | Not yet recruiting |
| Enrollment | 200 |
| Est. completion date | June 1, 2024 |
| Est. primary completion date | June 1, 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 19 Years and older |
| Eligibility | Inclusion Criteria: - Adult patients within Prism Vision Group with ICD diagnosis of acute posterior vitreous detachment and none of the ocular comorbidities listed as exclusion criteria will be screened as potential study participants. Exclusion Criteria: - Patients with vitreous hemorrhage, other significant media opacity or vitreoretinal pathology, or history of pars plana vitrectomy will be excluded. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Retina Group of Washington | Reston | Virginia |
| Lead Sponsor | Collaborator |
|---|---|
| Jeanette Du |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Symptom improvement assessed by questionnaire | NEI VFQ-25 = National Eye Institute Visual Function Questionnaire | Up to 2 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01970267 -
Clear Vision Study
|
N/A |